Target: IL-1 Beta Generic name: Canakinumab Product Origin: Recombinant in Human cells Canakinumab is a recombinant, human anti-human-IL-1- monoclonal antibody that belongs to the IgG1/- isotype subclass with a molecular mass of 145157 Daltons when deglycosylated. Canakinumab binds to human IL-1- and neutralizes its inflammatory activity by blocking its interaction with IL-1 receptors, but it does not bind IL-1alpha or IL-1 receptor antagonist (IL-1ra). References: 1. Church LD, McDermott MF: Canakinumab, a fully-human mAb against IL-1beta for the potential treatment of inflammatory disorders. Curr Opin Mol Ther. 2009 Feb,11(1):81-89. 2. Lachmann HJ, et al.: Use of canakinumab in the cryopyrin-associated periodic syndrome. N Engl J Med. 2009 Jun 4,360(23):2416-25. doi:10.1056/NEJMoa0810787
